Cumberland Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Cumberland Pharmaceuticals shares (CPIX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.09 – a decrease of 9.17% over the previous week. Cumberland Pharmaceuticals employs 91 staff and has a trailing 12-month revenue of around $36.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.09 |
|---|---|
| 52-week range | $1.07 - $2.36 |
| 50-day moving average | $1.24 |
| 200-day moving average | $1.54 |
| Wall St. target price | $8.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.76 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.11 from 2024-11-19
| 1 week (2024-11-14) | -7.50% |
|---|---|
| 1 month (2024-10-21) | -9.02% |
| 3 months (2024-08-21) | -20.14% |
| 6 months (2024-05-21) | -32.73% |
| 1 year (2023-11-21) | -35.09% |
|---|---|
| 2 years (2022-11-21) | -51.95% |
| 3 years (2021-11-19) | 2.49 |
| 5 years (2019-11-21) | 4.79 |
| Revenue TTM | $36.8 million |
|---|---|
| Gross profit TTM | $32.9 million |
| Return on assets TTM | -5.64% |
| Return on equity TTM | -36.07% |
| Profit margin | -29.55% |
| Book value | $1.77 |
| Market Capitalization | $16.9 million |
TTM: trailing 12 months
We're not expecting Cumberland Pharmaceuticals to pay a dividend over the next 12 months.
Cumberland Pharmaceuticals's shares were split on a 2:1 basis on 5 July 2007 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cumberland Pharmaceuticals shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cumberland Pharmaceuticals shares which in turn could have impacted Cumberland Pharmaceuticals's share price.
Over the last 12 months, Cumberland Pharmaceuticals's shares have ranged in value from as little as $1.07 up to $2.3587. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cumberland Pharmaceuticals's is 0.219. This would suggest that Cumberland Pharmaceuticals's shares are less volatile than average (for this exchange).
Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.